Oral News and Research

RSS

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Perrigo Company today announced results for its fourth quarter and full year ended June 26, 2010.

12 Aug 2010

Pharmasset receives fast track designation from FDA for PSI-7977

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.

12 Aug 2010

Nurses' Voices project covers oral history of nursing, development of new nursing practices

A research project giving nurses' first-hand accounts of life on the wards of St George's Hospital, London, over the last 80 years has been brought together in a new book.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

Oral sex becomes common activity among young women: Study

University of Alberta researcher Brea Malacad says results from a study on oral sex indicate there is little doubt that oral sex is becoming a more common activity for young women. Study results show the act has become a fundamental part of what Malacad calls the "sexual revolution of the 21st century". And she concludes that researchers, sex educators and marketers of safer-sex paraphernalia need to catch up with the trend.

12 Aug 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

11 Aug 2010

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced study initiation and dosing of the first patient in the Company's pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen in combination with levonorgestrel. The patch is applied once weekly for three weeks followed by a patch-free week.

11 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

Major bone-related meetings to take place in Valencia, Spain in March 2011

Two bone-related meetings, jointly organized by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and International Osteoporosis Foundation will take place in Valencia, Spain in March 2011.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

OptiNose Inc. announced today that a subgroup analysis of positive Phase II trial results has been published in the July/August issue of the American Journal of Rhinology & Allergy.

11 Aug 2010

New computerized approach for dental restoration procedures

Oral surgeons may one day have an easier, less costly approach to one important aspect of dental restoration, thanks to a newly patented process developed by researchers at Missouri University of Science and Technology (Missouri S&T).The process computerizes the method for creating a dental bar, also called an over-denture. For dental restoration procedures, the device is the bridge connecting dental implants to dentures.

11 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.

11 Aug 2010

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement with affiliates of Shire plc pursuant to which Noven will acquire global rights to Daytrana® (methylphenidate transdermal system) from Shire.

11 Aug 2010

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

11 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Water Pik sets up online community to support portfolio of oral health, shower head and sinus health products

In an effort to educate and inform consumers, Water Pik, Inc., a global leader in personal healthcare products, today announced the launch of its new online community on Waterpik.com. Powered by Lithium Technologies, the online destination supports Water Pik's entire portfolio of oral health, shower head and sinus health products and brings the company's experts, consumers and industry experts together in one digital space.

10 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

Oral News and Research

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Pharmasset receives fast track designation from FDA for PSI-7977

Nurses' Voices project covers oral history of nursing, development of new nursing practices

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Oral sex becomes common activity among young women: Study

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Major bone-related meetings to take place in Valencia, Spain in March 2011

Repros receives US patent for Androxal

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

New computerized approach for dental restoration procedures

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Water Pik sets up online community to support portfolio of oral health, shower head and sinus health products

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News